Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas

doi:10.3748/wjg.v29.i48.6179

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 48

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6892)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

239

WORD

HTML

3130

Figures (1-2)

491

Tables (1-2)

531

Sum=4451

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

294

Download

881

Sum=1175

Publishing Process of This Article

Item

Count

Browse

213

Download

864

Sum=1077

Dec 28, 2023 (publication date) through Mar 6, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Dec 28, 2023; 29(48): 6179-6197
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6179

Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas

Takuya Watanabe

Takuya Watanabe, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, Niigata 9502002, Japan

Author contributions: Watanabe T solely contributed to this manuscript.

Conflict-of-interest statement: There is no conflict of interest to disclose.

Corresponding author: Takuya Watanabe, MD, PhD, Director, Doctor, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, 1-2-21 Aoyama, Nishi-ku, Niigata 9502002, Japan. nabetaku@dia-net.ne.jp

Received: September 24, 2023
Peer-review started: September 24, 2023
First decision: October 29, 2023
Revised: November 2, 2023
Accepted: December 18, 2023
Article in press: December 18, 2023
Published online: December 28, 2023
Processing time: 93 Days and 22.1 Hours

Core Tip

Core Tip: Recently, the incidence of follicular lymphoma (FL) has increased in Asia, Europe, and the United States, with the number of gastrointestinal FL cases expected to increase. This article reviews the recent literature on the molecular origins of, innovative treatments for, and clinical trial findings on FL, focusing on gastrointestinal FL. Genetic factors [e.g., t(14;18) translocation and B-cell lymphoma 2 overexpression] drive FL growth, while microRNAs aid in its diagnosis and prognosis. Although recent trials have reported enhanced treatment outcomes, curative therapies remain elusive, and combinatorial regimens have not been optimized. Hence, gastroenterologists require a more comprehensive understanding of gastrointestinal FL pathogenesis to facilitate improved therapeutic outcomes.